NASDAQ: NIVFNewgenivf Group Ltd Stock
$0.75-0.23 (-23.47%)
Updated Oct 14, 2024
NIVF Price
$0.75
Fair Value Price
$1.22
Market Cap
$7.65M
52 Week Low
$0.55
52 Week High
$17.24
P/E
4.19x
P/B
8.54x
P/S
1.31x
PEG
N/A
Dividend Yield
N/A
Revenue
$5.14M
Earnings
$130.19k
Gross Margin
32.7%
Operating Margin
3.43%
Profit Margin
2.5%
Debt to Equity
1.39
Operating Cash Flow
-$2M
Beta
0.32
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
NIVF Overview
A SPAC I Acquisition Corp. is a "blank check" formed to effect mergers, share exchanges, asset acquisitions, stock purchases, reorganizations, or similar business combinations. It targets the technology, media, and telecom sectors in the U.S. and Asia. The company was incorporated in 2021 and is based in Singapore.
Zen Score
–
Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how NIVF scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NIVF ($0.75) is undervalued by 38.11% relative to our estimate of its Fair Value price of $1.22 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
NIVF ($0.75) is significantly undervalued by 38.11% relative to our estimate of its Fair Value price of $1.22 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
NIVF was unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more NIVF due diligence checks available for Premium users.
Be the first to know about important NIVF news, forecast changes, insider trades & much more!
NIVF News
Valuation
NIVF fair value
Fair Value of NIVF stock based on Discounted Cash Flow (DCF)
Price
$0.75
Fair Value
$1.22
Undervalued by
38.44%
NIVF ($0.75) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
NIVF ($0.75) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
NIVF was unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
NIVF price to earnings (PE)
For valuing profitable companies with steady earnings
Company
4.19x
Industry
-5.48x
Market
27.44x
NIVF is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
NIVF is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
NIVF price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
8.54x
Industry
5.1x
NIVF is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
NIVF's financial health
Profit margin
Revenue
$5.1M
Net Income
-$134.4k
Profit Margin
-2.6%
NIVF's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
NIVF's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$1.6M
Liabilities
$1.2M
Debt to equity
1.39
NIVF's short-term assets ($1.20M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NIVF's short-term assets ($1.20M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NIVF's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.1M
Investing
-$33.0M
Financing
$34.1M
NIVF's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
NIVF vs Medical Care Facility Stocks
Newgenivf Group Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.